The innate lymphoid cells (ILCs) are a novel lymphocyte subfamily that is distinguished from the T cells and B cells of the adaptive immune system by their lack of clonotypic antigen receptors and by their independence from the DNA rearrangement machinery (they develop in the absence of recombination-activating gene 1 (Rag1) or Rag2). Morphologically, ILCs resemble lymphoid cells and, similarly to B cells and T cells, they develop from common lymphoid progenitors (CLPs) that express CD127 (also known as IL-7Rα). Moreover, mature ILCs express the characteristic surface receptors and effector molecules of differentiated T cell subsets under the control of specific transcription factors, which underlines their similarities to their adaptive lymphoid counterparts. Nevertheless, although adaptive immune responses normally require days to weeks in order to fully differentiate, ILCs are early effectors of immunity that respond within hours after activation. As such, ILCs and T cells can be viewed as providing coherent effector functions that differ mostly with regards to kinetics.
ILCs have been categorized into three major groups on the basis of their phenotypic and functional similarities to T helper (T H ) cells (reviewed in REFS 1, 2) (FIG. 1) . Group 1 ILCs (referred to here as ILC1s) produce T H 1-type cytokines (such as interferon-γ (IFNγ)) and include natural killer (NK) cells as well as other IFNγ-producing ILCs. Group 2 ILCs (referred to here as ILC2s) produce T H 2-type cytokines (such as interleukin-5 (IL-5) and IL-13) and include natural helper cells, nuocytes and innate helper 2 cells. Group 3 ILCs (referred to here as ILC3s) comprise several phenotypically distinct subsets, including lymphoid tissue-inducer (LTi) cells and mucosal natural cytotoxicity receptor (NCR)-bearing cells that produce the T H 17-type cytokines IL-17A and IL-22. Although this classification is based on certain 'signature' features of ILCs, it should be emphasized that the range of functional abilities of different ILC groups is not fully appreciated, leaving room for further refinement (and possible redefinition) of the ILC nomenclature. Still, the current ILC grouping is supported by the remarkable degree of conservation between ILCs in mice and humans.
Our knowledge of the signals and mechanisms that regulate ILC differentiation from haematopoietic precursors is still in its infancy. In this Review, we examine the transcription factor pathways that regulate ILC development, differentiation and stability. A better understanding of the critical stages and regulators of ILC differentiation could eventually lead to new experimental or therapeutic approaches for manipulating the immune system in the early stages of pathogenic infection or during inflammatory disease.
Transcriptional regulation of innate lymphoid cell fate
Nicolas Serafini, Christian A. J. Vosshenrich and James P. Di Santo Abstract | Innate lymphoid cells (ILCs) are a recently described family of lymphoid effector cells that have important roles in immune defence, inflammation and tissue remodelling. It has been proposed that ILCs represent 'innate' homologues of differentiated effector T cells, and they have been categorized into three groups -namely, ILC1s, ILC2s and ILC3s -on the basis of their expression of cytokines and transcription factors that are typically associated with T helper 1 (T H 1)-, T H 2-and T H 17-type immune responses, respectively. Indeed, remarkable similarity is seen between the specific transcription factors required for the development and diversification of different ILC groups and those that drive effector T cell differentiation. The recent identification of dedicated ILC precursors has provided a view of the mechanisms that control this first essential stage of ILC development. Here, we discuss the transcriptional mechanisms that regulate ILC development and diversification into distinct effector subsets with key roles in immunity and tissue homeostasis. We further caution against the current distinction between 'helper' versus 'killer' subsets in the evolving area of ILC nomenclature.
ILC subsets
ILC1s: including NK cells and other IFNγ-producing innate cells. The first member of the ILC family was discovered ~40 years ago, when NK cells were character ized in mice and humans (reviewed in REFS 3, 4) . Functionally, NK cells are able to eliminate infected or 'stressed' target cells by releasing cytotoxic granules or by mechanisms involving cell surface-associated FAS ligand (FASL; also known as CD95L) or tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) 5 . As such, NK cells are crucial players in tumour immunosurveillance. In addition, NK cells are potent producers of cytokines -notably, T H 1-type cytokines (including IFNγ and TNF) -which is especially important in the context of infections by intracellular bacteria. Interestingly, requirements for NK cell cytotoxicity and cytokine production depend on the disease context; in some cases, NK cell 'killing' is redundant for NK cell-mediated immune protection in certain organs 6 . Although both mouse and human NK cells uniformly express the NCR NKp46, there is substantial heterogeneity within these populations in both species. Human hi NK cell subsets express the transcription factor eomesodermin (EOMES), are cytotoxic and produce cytokines (FIG. 1) .
Heterogeneous NK cell subsets in the mouse include CD27 + CD11b − and CD27 − CD11b + NK cells that are found throughout the body (FIG. 1) . Specialized NKp46 + NK1.1 + cell subsets with distinct functional properties have been described in the thymus, liver, pancreas and uterus (reviewed in REFS 3, 4) , and more recently in mucosal sites 8, 9 . These cells share the expression of NKp46, NK1.1 and NKG2D with conventional NK cells; they are T-bet + and produce T H 1-type cytokines. In contrast to NK cells, these NKp46 + NK1.1 + cells lack expression of MHC-specific inhibitory receptors and α2 integrin (also known as VLA2 or CD49b), and they also do not express Eomes, which renders them devoid of perforin and granzyme-mediated cytotoxic granules. Instead, they express the α1β1 integrin (also known as VLA1 or CD49a-CD18) and Tnfsf10 (which encodes TRAIL), which allows them to eliminate target cells through a granzymeindependent pathway 5, 10 . Thus, two T-bet + IFNγ-producing ILC1 subsets exist in mice: one that expresses Eomes and harbours cytotoxic granules, and one that lacks Eomes expression but expresses TRAIL. Studies using Eomes-reporter mice suggest that these two ILC1 subsets have stable phenotypic and functional characteristics 9, 11 . In humans, a liver-resident subset of CD49a + CD56 hi NK cells also exists that expresses T-bet but not EOMES 12 . In addition, an unusual tonsillar ILC1 subset has been identified 13 . These CD161 + T-bet + cells produce abundant IFNγ but lack NK cell markers (including NKp46, CD56, CD16 and CD94) and do not produce perforin or granzyme B. It is not known whether these human CD161 + T-bet + cells express TRAIL. Interestingly, this novel human ILC1 subset was enriched in mucosal tissues and expanded following intestinal inflammation, suggesting a role for these cells in mucosal pathologies 13 . How should we classify these different IFNγ-producing ILCs? Clearly all of these cells are ILC1s as they express T-bet and promptly produce type 1 cytokines. Recently, the case has been made to consider a separate 'killer' ILC lineage (including most conventional Nature Reviews | Immunology . We would argue against this nomenclature as NK cells and other ILCs have more common features than differences, especially with regards to 'helper' functions
. We instead propose that two ILC1 subsets should be distinguished: EOMES + ILC1s (which includes NK cells) and EOMES − ILC1s (FIG. 1) . The developmental pathways and transcription factors that condition generation of these different ILC1 subsets are described in detail below.
ILC2s: including natural helper cells, nuocytes and innate helper 2 cells. Several groups have described ILC subsets that abundantly produce type 2 cytokines, including IL-5, IL-9 and IL-13 . These cell populations were initially denoted 'natural helper cells' , 'nuocytes' , or 'innate helper 2 cells' (REFS [14] [15] [16] but were more recently designated as ILC2s 1,2 . ILC2s express IL-25R (also known as IL-17RB), IL-33R (also known as T1, ST2 or IL1RL1) and the receptor for thymic stromal lymphopoietin (TSLP) (FIG. 1) . As such, they are poised to respond rapidly to IL-25, IL-33 and TSLP produced by epithelial cells and haematopoietic cells during inflammation or infection [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . In mice, ILC2s are distributed in the blood, in lymphoid tissues (such as the spleen and bone marrow), in non-lymphoid tissues (including the liver, kidneys and visceral adipose tissue) and in mucosal tissues (such as the lungs, intestine and fat-associated mesenteric lymphoid clusters) 14, 16, [23] [24] [25] . In addition to producing IL-5 and IL-13, ILC2s can also produce IL-2, IL-6, granulocytemacrophage colony-stimulating factor (GM-CSF) and the epidermal growth factor-related protein amphiregulin 14, 15, 17, 22, 25 . Consequently, ILC2s promote eosinophil recruitment 26 and homeostasis (by IL-5 production) 23 , proliferation of mast cells 27 and T cells (by IL-9 production) 27 , and mucus production by goblet cells (by the secretion of IL-13) [14] [15] [16] . Interestingly, ILC2 homeo stasis and proliferation may be driven in an autocrine manner by IL-9 production 27 and by the interaction of ILC2s with antigen-specific T cells through the expression of MHC class II 28 . Moreover, ILC2-derived IL-13 promotes dendritic cell migration into draining lymph nodes for the priming of T H 2 cell responses 29 . ILC2s are activated during parasitic worm infections [14] [15] [16] , viral infections 21, 22 and allergic reactions 30 , and they are also associated with chronic human diseases such as atopic dermatitis 31 , pulmonary fibrosis 32 and hepatic fibrosis 33 . ILC2s have also been characterized in human fetal and adult tissues and in the circulation. Human ILC2s express T H 2 chemoattractant receptor (CRTH2; also known as CD294) that serves as a high-affinity receptor for prostaglandin D2 and is also expressed by T H 2 cells. Both mouse and human ILC2s express high levels of the transcription factor GATA-binding protein 3 (GATA3) 24, [34] [35] [36] [37] , which regulates ILC2 development and is crucial for type 2 cytokine secretion 22, 24, 35, 36, 38 . Several other transcription factors -including Notch, T cell factor 1 (TCF1; also known as HNF1α) and retinoic acid receptor-related orphan receptor-α (RORα) -are crucial for ILC2 generation, as discussed below. Increased ILC2 numbers and activation have been demonstrated in human inflammatory syndromes, including allergic asthma and airway hyperreactivity 39 . Recently, ILC2s have been shown in both mice and humans to regulate metabolic tone through 'beiging' of adipose tissue by secreting Met-encephalin peptides 40, 41 . The degree to which ILC2s are functionally heterogeneous remains unclear. Subsets of ILC2s in the bone marrow, lymphoid tissues or lungs of humans and mice differentially express CC-chemokine receptor 6 (CCR6), CCR9, CD117, CD25, killer cell lectin-like receptor subfamily G member 1 (KLRG1) and/or SCA1 (reviewed in REF. 42 ). Whether these subsets represent immature 44 into isolated lymphoid follicles that support the generation of IgA-producing plasma cells 45, 46 . LTi cells were subsequently shown to play a part in immune defence against infection during adult life through production of the pro-inflammatory cytokines IL-17A and IL-22 (REFS 47, 48) . LTi cells acquire these diverse functions owing to their expression of the transcription factor RORγt, which is essential for their generation 47, 49, 50 .
More recently, other RORγt-dependent ILC3 subsets were identified, such as NCR + cells, which express NKp46 in mice and NKp44 in humans. These NCR In both mice and humans, NCR + ILC3s are enriched in mucosal sites (such as the intestinal lamina propria and Peyer's patches), but they are rare in other lymphoid tissues, including the spleen and peripheral lymph nodes, at steady state 51, 52, [54] [55] [56] . Commensal bacteria in the gut are involved in the homeostasis of NKp46 + ILC3s in mice 51, 52 , but the mechanisms involved are unclear. In addition, heterogeneous CD4 − NCR − ILC3 subsets have been described that express combinations of CCR6, T-bet and MHC class II and produce IL-17A, IL-22 and IFNγ 54, 55, 57 . Some of these RORγt + ILCs seem to be pathogenic and are associated with colonic inflammation in mouse models (Helicobacter hepaticus infection and inflammation induced by CD40-agonistic antibodies) 54 . By contrast, a fraction of ILC3s constitutively express MHC class II molecules and seem to have a role in maintaining intestinal T cell homeostasis and activation 57 . Therefore, in terms of their protective or pathogenic functions, distinct subsets of RORγt + ILC3s are remarkably diverse. Understanding the role of distinct ILC3 subsets in immune defence and tissue homeo stasis is challenging but could provide important information that could translate to better disease prevention or treatment. Several inflammatory diseases in humans (for example, inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis) are associated with excessive IL-23 activity that leads to high levels of IL-17 and/or IL-22 (REF. 58 ). In humans, cytokine-producing ILC3s are found in intestinal tissues 59, 60 , lymph nodes 61 , tonsils, Peyer's patches and the appendix 62 . In patients with IBD, the homeostasis of IL-22-and IL-17-producing ILC3 populations seems to be disturbed 63 . However, more work is required in order to fully understand the complexity of ILC3 subsets and to firmly establish the roles of these subsets in healthy and diseased human tissues.
Other 'innate' effector cells have been described that share some functional characteristics with ILCs, although these cell types also have some clear developmental differences (see BOX 2) . Are these cells ILCs? What criteria should be used to include immune effectors in the ILC family? The characterization of distinct groups of ILCs and heterogeneous subsets within individual ILC groups underscores the remarkable degree of ILC diversity. This diversity, however, raises new questions: what are the developmental pathways that guide differentiation of ILC subsets? How is ILC diversification achieved? Where does ILC differentiation occur? Are ILC subsets functionally fixed or plastic? We address these questions in the subsequent sections.
ILC development
Within the haematopoietic system, multipotent, selfrenewing haematopoietic stem cells (HSCs) provide the cellular substrate for the generation of all haemato poietic lineages (that is, erythroid, megakaryocytoid, myeloid and lymphoid cells). Haematopoiesis is a continuous process that is characterized by the progressive loss of cell-fate potentials. During lymphopoiesis, erythroid, megakaryocytoid and myeloid potentials are lost, resulting in the generation of common lymphoid progenitors (CLPs) that are restricted to the lymphoid fate. Several Box 2 | iCD8αα cells: to be or not to be an ILC?
Common lymphoid progenitor (CLP)-derived innate lymphoid cells (ILCs) are an important effector population for innate immune responses. Do other ILC subsets exist? Recently, a new innate cell population was described that is characterized by the expression of CD8α homodimers ('iCD8αα' cells) 150 . Localized in the intestinal epithelium, iCD8αα cells lack CD127 expression (unlike most ILCs) and instead express a constellation of markers that are not routinely found on ILCs (including CD11b, CD11c, CD16-CD32, CD103, lymphocyte activation gene 3 protein (LAG3) and the MHC class Ib protein H2-T3 in mice). Nevertheless, iCD8αα cells are derived from CLPs and show evidence for previous expression of recombinase-activating gene 1 (Rag1; that is, fate mapped in Rag1
Cre reporter mice) similar to that recently shown for NK cells and ILC3 (REF. 151 ). The relationship of iCD8αα cells to NK cells is also evident from their expression of CD122 and their dependence on IL-15 for normal development. However, iCD8αα cells develop independently of inhibitor of DNA binding 2 (ID2), which is an essential orchestrator of ILC differentiation. Taken together, iCD8αα cells seem to defy any simple classification into known haematopoietic lineages. Interestingly, iCD8αα + cells seem to be involved in defence against bacteria, and they express granzymes and interferon-γ (IFNγ) after interleukin-12 (IL-12)-mediated activation. iCD8αα + cells also interact with the others immune cells by secretion of CC-chemokine ligand 2 (CCL2), CCL4, CCL5 and CXC-chemokine ligand 2 (CXCL2) and demonstrate antigen-presentation capacity after phagocytosis. More work will be required in order to understand the developmental relationships between iCD8αα cells and other haematopoietic cells and their place within innate immune defence.
transcription factors are involved in CLP generation (including Ikaros, E2A (also known as TCF3), PU.1 and growth factor independent 1 (GFI1)) and seem to prime the lymphoid programme even at the earliest stages (that is, the HSC stage) of this process 64 . These transcription factors concomitantly activate the lymphoid-restricted gene programmes (including expression of Cd127, Rag1 and Rag2) and strongly repress the myeloid programme. The result is a cell population that has restricted potential for B cell, T cell and ILC fates. We propose that ILC development should be considered to have three main stages: 'stage 1' , the generation of common ILC precursors (CILCPs); 'stage 2' , the diversification of ILC precursors (ILCPs) into each of the three main ILC groups; and 'stage 3' , ILC maintenance and regulation in peripheral tissues (FIG. 2) . 3 ). Immature NK (iNK) cells appear after expression of eomesodermin (EOMES), thymocyte selection-associated high mobility group box protein (TOX) and ETS1 in NK precursors (NKPs) and mature cells under the influence of T-bet and runt-related transcription factor 3 (RUNX3). ILC1s may derive from NKPs and/or CHILPs in response to an IL-15-induced transcriptional programme that involves transcription factors such as T-bet, EOMES, GATA-binding protein 3 (GATA3) and/or NFIL3. ILC2s and ILC3s can differentiate from the ID2 + CHILPs under the influence of specific transcription factors, IL-7 and retinoic acid. Interestingly, environmental factors, and notably the commensal flora, influence the stability of some of transcription factors expressed by ILCs, such as retinoic acid receptor-related orphan receptor-γt (RORγt). The dashed arrow and dashed cell outlines indicate hypothetical pathways and precursors. AHR, aryl hydrocarbon receptor; DN, double negative for CD4 and natural cytotoxicity receptors (NCRs); GFI1, growth factor independent 1; LTi, lymphoid tissue-inducer; TCF1, T cell factor 1. 66 . By excluding all differentiated lymphocyte subsets, rare populations remain that have the characteristics of committed ILCPs. Several groups recently identified these cells using mice that report on inhibitor of DNA binding 2 (Id2), Zbtb16 (which encodes promyelocytic leukaemia zinc finger (PLZF)) or CXC-chemokine receptor 6 (Cxcr6) expression 9, [67] [68] [69] . These precursors have been denoted common helper ILCPs (CHILPs), PLZF + ILCPs and α-lymphoid precursors (αLPs); in this Review, these different ILCPs are referred to as CILCPs for simplicity (FIG. 2) .
CILCPs lack B cell and T cell potential, have no myeloid potential and give rise to the three main ILC groups after adoptive transfer in vivo. Moreover, in vitro, CILCPs can give rise at the single-cell level to multiple ILC groups and in the case of CXCR6 + CILCPs, can generate EOMES + ILC1s as well as EOMES − ILC1s, ILC2s and ILC3s at the single-cell level 69 . These studies provide strong evidence that committed ILCPs exist in mice, although the functional characteristics of these CILCP populations are somewhat distinct, suggesting further complexity. For example, ID2 + and PLZF + ILCPs seem to lack potential to become EOMES + ILC1s (that is, NK cells), whereas PLZF + ILCPs also failed to generate LTi cells of the ILC3 subset in vivo or in vitro 9, 68 . These observations suggest a model in which CILCPs may progressively lose the ability to generate particular ILC subsets as they differentiate: in this scenario, CXCR6 + CILCPs would represent the most 'immature' CILCPs, whereas PLZF + ILCPs would be more 'mature' precursors (FIG. 3a) . The fact that PLZF expression can be induced in CD127 + α4β7 + cells by Notch signalling 68 is consistent with this model. Alternatively, these different CILCPs may indicate unique pathways of ILC development due to transcription factor requirements (FIG. 3b; but also see BOX 1) . Studies assessing the precursor-product relationships of these different CILCPs with direct side-by-side comparison for in vitro and in vivo potential should help to resolve these issues.
Along these lines, an additional discussion concerning committed NK precursors (NKPs) is warranted. Although the existence of NKPs has been known for some time 70 , a more recent characterization helped to further define NKP generation from CLPs 71, 72 . Transcription factors that promote CILCP generation. Several transcription factors have been identified that affect the generation of multiple ILC subsets, including ID2, nuclear factor IL-3 induced (NFIL3; also known as E4BP4) and GATA3 (FIG. 2) . The broad effect of ablation of these transcription factors on ILC homeostasis can be explained in part by their role in promoting emergence of ILCPs from CLPs. Here, we briefly summarize how selected transcription factors may orchestrate this process.
ID2. ID2 is a member of the ID family of transcriptional repressors, which broadly regulate cellular differentiation in different organ systems. ID proteins lack a DNAbinding domain and thus do not have the ability to directly modulate gene transcription. They instead act indirectly by binding to and functionally inactivating a set of transcriptional activators (the so-called 'E proteins') that includes E2A, E2-2 (also known as TCF3) and HEB (also known as TCF12). Within the haematopoietic system, ID2 is expressed in multiple cell lineages and its ablation has diverse effects on the differentiation of myeloid and lymphoid cells (reviewed in REF. 73 ). An early report described a selective loss of NK cells and lymphoid tissues in ID2-deficient mice [74] [75] [76] . As primary B cell and T cell development was essentially unperturbed in these mice, a model emerged in which levels of E protein activity would dictate the choice between, on the one hand, B cells and T cells and, on the other hand, NK cells in early lymphoid precursors. Consistent with this model, early B cell-and T cell-lineage development is strongly perturbed in mice deficient for E2A, E2-2 and/or HEB [77] [78] [79] . Since then, ID2 has been shown to be essential for the development of all known ILC subsets 8, 13, 49, 65, 73 reinforcing this general principle. Moreover, overexpression of ID proteins inhibits B cell and T cell development, while strongly promoting ILC (specifically NK cell) generation 80 . As CLPs express little or no ID2 (REFS 9, 35, 68) , the signals that regulate its expression should strongly affect the choice of B cell or T cell versus ILC development by altering the overall E protein activity within these precursors. High levels of ID2 would essentially restrict lymphoid precursors to the ILC lineage, a model consistent with the characteristics of ID2 + and PLZF + CILCPs 9, 68 . Bone morphogenic proteins (BMPs) trigger the SMAD pathway and seem to directly regulate ID2 transcription in some cell types 81 . By contrast, signals that maintain E protein activity in CLPs would counteract this process. Interestingly, some ILCs can develop in the absence of ID2 if E proteins are also ablated 74 . These observations suggest that ILC development might represent a default pathway for CLPs.
NFIL3.
The transcriptional regulator NFIL3 is broadly expressed in multiple tissues and is involved in multiple developmental and biological processes, including the regulation of circadian rhythms 82, 83 . NFIL3 can be associated with either activating or repressive functions depending on its assembly with other cofactors. Within the haematopoietic system, NFIL3 has multiple roles and regulates development and differentiation of several different lineages (reviewed in REF. 84 ). Within lymphocytes, NFIL3 ablation has a dramatic effect on NK cell development at the pre-NKP stage, but NFIL3 expression does not seem to be essential in mature NKp46 + cells 85, 86 . Recently, several groups have described defects in multiple ILC subsets in NFIL3-deficient mice -including a loss of IFNγ + intestinal ILC1s, variable defects in ILC2s and reduced numbers of ILC3s -that result in impaired mucosal defences 34, 87, 88 . The broad effect of NFIL3 loss on several ILC groups suggests a role for this transcription factor in early lymphopoiesis and possibly in the generation of CILCPs. This seems to be the case, as PLZF + CILCPs and ID2 + CILCPs express high levels of NFIL3 and are greatly reduced in number in the absence of NFIL3 (REFS 69, 89) . Thus NFIL3 seems to be an important orchestrator of ILCP emergence from CLPs.
As is the case for ID2, CLPs express little if any NFIL3, so signals that regulate NFIL3 expression could affect B cell, T cell and ILC fate decisions in these early precursors. NFIL3 levels can be regulated by cytokines 90 , and IL-7 can strongly induce NFIL3 expression in CLPs and CILCPs. Once expressed, NFIL3 can influence transcriptional profiles, although relevant NFIL3 targets in early lymphoid precursors are not clearly identified. One possibility is that NFIL3 represses B cell or T cell programmes, thereby promoting an ILC fate. ID2 would be a logical candidate for NFIL3-mediated activation, although ID2 levels are apparently not altered in NFIL3-deficient NK cells 91 or NFIL3-deficient ILC2s 89 . However, NFIL3 could control ID2 at an earlier stage, and evidence for activated dimethylated H3K4 in the NFIL3-binding region of ID2 in CILCPs has recently been demonstrated 89 . Other targets that may be activated by NFIL3 include the transcription factors thymocyte selection-associated high mobility group box protein (TOX) and EOMES 69, 92 , although no clear evidence has been provided that these transcription factors broadly affect ILC homeostasis. More work is required to understand how NFIL3 expression is controlled and to determine the relevant NFIL3 targets in CLPs and ILCPs.
GATA3.
The transcription factor GATA3 has many roles in T cell differentiation, allowing for the generation of the earliest T cell progenitors, promoting several stages of thymocyte differentiation and being involved later as an essential driver of T H 2 cell polarization (reviewed in REF. 93 ). As expected, GATA3 has a crucial role throughout ILC2 differentiation in ensuring IL-5 and IL-13 expression 23, [34] [35] (see more below) but, somewhat surprisingly, it is also required for development of several ILC1 and ILC3 subsets 9, 36, 94, 95 . In the absence of GATA3, lin − CD127
+ cells fail to develop in the fetal liver and adult bone marrow, and mature intestinal EOMES − ILC1s and all ILC3 subsets (CD4 + LTi cells and NCR + cells) are missing 9, 95 . As such, GATA3 has a broad role in ILC development. It has been proposed that GATA3 segregates 'helper' from 'killer' ILC lineages 96 , the overall effects of GATA3 deletion on ILC development may be explained by the lack of IL-7 signalling. An in-depth characterization of CILCPs in GATA3-deficient mice may provide answers.
PLZF.
Zbtb16 encodes the transcription factor PLZF, which has crucial roles in the differentiation of T cell subsets, especially that of CD1d-reactive invariant NKT cells (reviewed in REF. 98 ). Recently, the role for PLZF in ILC differentiation was demonstrated using Zbtb16 CreGFP mice 68 . As indicated above, PLZF + fetal liver and bone marrow precursors were shown to include committed ILCPs. However, Zbtb16-deficient mice do not show widespread defects in ILC development but, rather, have selective and partial defects in ILC1 and ILC2 development 68 . It is therefore unlikely that PLZF expression is required for the generation of CILCPs from CLPs, although the molecular targets of this transcription factor are still unknown.
Stage 2: diversification of three main ILC groups Parallels between ILC and T H cell differentiation.
The second stage of ILC differentiation involves the diversification of different ILC groups from committed CILCPs (FIG. 2) . Although strong evidence indicates that different transcription factors regulate this process (as described below), the signals that initiate ILC diversification are poorly defined. Considering the strong parallels between mature ILC subsets and differentiated T cell subsets, one model for ILC differentiation draws heavily on the current knowledge of T H cell diversification from naive T cells. This process generates T H cells that express signature transcription factors and cytokines; an analogous process could regulate the differentiation of ILC subsets (that is, T-bet and IFNγ in ILC1s; GATA3, IL-5 and IL-13 in ILC2s; and RORγt, IL-17 and IL-22 in ILC3s) (see also BOX 3) . During T H cell differentiation, several signals are required, including T cell receptor triggering, co-stimulation and soluble factors (these have been referred to as signal 1, signal 2 and signal 3, respectively; reviewed in REF. 99 ). T cell receptor signalling activates an immunoreceptor tyrosine-based activation motif (ITAM)dependent pathway that involves the SYK and ZAP70 tyrosine kinases. Co-stimulation triggers a phosphoinositide 3-kinase pathway that assures robust T cell proliferation, whereas cytokines associated with signal 3 provide guidance for T H cell polarization. Are analogous signals involved in ILC differentiation? Do 'naive' undifferentiated ILCs exist? In short, there are too few data to conclude for or against the 'T H cell' model of ILC diversification. It is not known whether ITAM signals are required for ILC development (except for in the case of NK cells, in which these signals are not required 100 ). Similarly, the importance of co-stimulation for ILC diversification has not yet been demonstrated. Expression of some cytokine receptors can be redundant for the generation of certain ILC subsets (for instance,
Box 3 | The evolutionary relationship between ILC subsets and T H cells
Which came first (evolutionarily speaking): innate lymphoid cells (ILCs) or T helper (T H ) cells? One can imagine that pressure to develop diversified defences evolved as the microbial world expanded. In addition to cellular mechanisms of phagocytosis, more sophisticated systems involving cellular barriers, soluble antimicrobial factors and diverse effector cells were needed. This necessitated coordination between different cell types that probably led to the well-characterized present day 'type X' responses that combat viruses, intracellular and extracellular bacteria, fungi and parasites. Before the emergence of antigen receptors, ILCs would have evolved to be part of this new defence system. The fitness advantage afforded by diversified ILC groups would be twofold: first, ILCs could act to relay primary events of infection to the appropriate effector cells; in this way ILCs (like sentinel cells) interpret immunity. Second, ILCs could act to amplify the response due to robust cytokine production and probably through cell proliferation. With the advent of T cell receptors, adaptive T H cells would co-opt this 'blueprint' and embellish it with additional features, including fine antigen specificity, clonal expansion and long-lived immunological memory. As such, the idea that ILCs were precursors to T H cells makes sense. However, ILCs are developmentally dependent on inhibitor of DNA binding 2 (ID2)-mediated repression of E protein-driven B cell and T cell development. If ILCs evolved first, then how can one explain the selective pressure to develop ID2 to counteract B cell and T cell pathways that don't exist? One possibility is that ILCs may have initially needed ID2 (and other IDs) for another reason: to diverge from primitive proliferating haematopoietic stem cells (that express high levels of E protein). Further studies in invertebrate species will hopefully provide the answers to these questions.
ILC1, ILC2 and NKp46
+ ILC3 subsets can develop in the absence of IL-12R, IL-33R and IL-23R signalling, respectively) 15, 51, 101 . However, whether these factors provide relevant signals at the ILCP stage and whether ILCPs should be considered to be 'innate' versions of naive T cells is not clear.
Whatever the requisite signals, selective upregulation of signature transcription factors marks the initial step towards diversification into different ILC groups. In some cases, immature stages that represent steps along the path to mature ILCs have been distinguished. Here, we briefly summarize these ILC group-restricted precursors and explain how certain transcription factors guide their differentiation into distinct mature ILC subsets.
Differentiation of ILC1s.
Transcription factors that influence ILC1 commitment include T-bet, EOMES, ETS1 and TOX 11, [102] [103] [104] . T-bet (encoded by Tbx21) is the signature transcription factor for mature ILC1s that produce IFNγ. T-bet binds to and activates the Ifng locus via chromatin remodelling that allows additional binding of factors that upregulate Ifng expression, such as runt-related transcription factor 3 (RUNX3) 105 .
Committed precursors for EOMES
+ ILC1s (that is, NK cells) are well characterized and include NKP subsets that express T-bet and EOMES 92 . Committed precursors for EOMES − ILC1s are proposed to include CD127 + NKp46 + NK1.1 + bone marrow cells 9 , but these cells have not been rigorously studied. Inducers of T-bet expression in differentiating T H 1 cells include signal transducer and activator of transcription 1 (STAT1) and STAT4, which are activated in response to IFNγ and IL-12, respectively (reviewed in REF. 106 ). Whether these soluble factors and their associated STAT pathways are involved in early stages of ILC1 commitment from ILCPs is not known. EOMES has been proposed as a downstream target of NFIL3 in NKPs 92 that might drive early stage differentiation and could help to explain the strong defect in NK cell development in NFIL3-deficient mice. However, as these mice have defects in several ILC subsets (including EOMES − ILC1s 9, 69, 87, 88 ), it is likely that NFIL3 activates many targets in addition to EOMES. Eomes-and Tbx21-reporter mice will be important tools for identifying ILC1 precursors in future studies.
The transcription factor TOX has several roles during intrathymic T cell selection and differentiation 107, 108 . TOX is expressed at low levels by CLPs 69 and is also expressed by a subset of PLZF + CILCPs
68
. TOX-deficient mice lack NKp46 + NK cells in the bone marrow and spleen, suggesting that this transcription factor has an important role in ILC1 development, at least for EOMES + ILC1s
102
. The additional effect of TOX deficiency on ILC3 development (see below) could indicate a role for this transcription factor in a subset of multipotent ILCPs. Along these lines, NFIL3 has been proposed to regulate TOX expression in a subset of CILCPs 69 . ETS1 is a member of the large family of ETS transcription factors (there are 26 members of the ETS family in mice), and it has widespread roles in development (reviewed in REF. 109 ). ETS1 deficiency affects multiple lymphoid lineages, including B cells, T cells and NK cells 104, 110, 111 . Pre-NKP numbers are reduced in the absence of ETS1, and transcriptional analyses indicate that ETS1 sustains ID2 and T-bet expression in these progenitors 112 . Upstream regulators of ETS1 in lymphoid precursors are poorly characterized but include the cytokines IL-2 and IL-15 in more mature cells.
Differentiation of ILC2s
. Several transcription factors have been identified that are crucial to ILC2 subset differentiation, including GATA3, GFI1, TCF1 and RORα 17, 24, 35, 36, [113] [114] [115] . GATA3 is considered a signature transcription factor for mature ILC2s, and cell populations expressing high levels of GATA3 are highly enriched for these cells 24, 35, 36, 95 . GATA3 transcriptional activity activates type 2 cytokine transcription and is required for effector functions in mature ILC2s as well as for their survival 38 . Lower levels of GATA3 are expressed in CILCPs, so GATA3 upregulation marks the stage of restriction and commitment to the ILC2 lin eage. What regulates GATA3 expression at this stage is unknown, but STAT6 may be involved as is the case in differentiating T H 2 cells (reviewed in REF. 93 ). GATA3 hi ILC2s can be found in the bone marrow and are proposed to be ILC2 precursors because of their superior proliferative capacity 35 . However, bone marrow ILC2s produce type 2 cytokines 35 , so they cannot be considered to be functionally immature. 113, 115 , its role in vivo in this process is still unclear. By contrast, TCF1 is essential for ILC2 development in vivo 115, 118 , suggesting close parallels exist between ILC2 development and early T cell development. Considering the close relationship between Notch, TCF1 and BCL11B, it is possible that the latter is also involved in ILC2 development.
RORα is a transcription factor of the nuclear hormone receptor superfamily. It is required for several developmental processes, most notably for cerebellar Purkinje cell generation as can be seen from the cere bellar defects that occur in 'staggerer' mice, which harbour a deletion within Rora 119 . Rora is highly expressed by multiple ILC subsets 113, 120, 121 , but its ablation causes a selective defect in ILC2 numbers, especially in the bone marrow 113, 120 . The factors that induce RORα in the ILC2 lineage are not known but could include GATA3 (REF. 24 ). The downstream targets of RORα that promote ILC2 differentiation are similarly undefined.
Differentiation of ILC3s. The orphan nuclear hormone receptor transcription factor RORγt is essential for the development of ILC3s 49, [51] [52] [53] 56 . Expression of RORγt in early haematopoietic precursors marks cells that have committed to the ILC3 lineage; these include fetal liver α4β7 + cells in mice 50 as well as a subset of CD34 + CD117 + cells in humans 122 . RORγt expression in both mouse and human ILC3 precursors is associated with several hallmarks of mature ILC3s (for example, expression of aryl hydrocarbon receptor (AHR), IL1R, IL23R and TOX); however, the expression of cytokines such as IL-17 and IL-22 in these cells is rather limited, suggesting that additional signals are required to fully mature these ILC3 precursors 55, 102, [123] [124] [125] [126] [127] . Curiously, these RORγt + precursors are extremely rare in adult mouse bone marrow. Together, these observations are consistent with the possibility that immature ILCPs (common or grouprestricted) may exit the bone marrow and complete their differentiation within tissues (see below). The factors that drive RORγt expression at this stage are not fully understood, but transient Notch signals have been proposed to contribute, especially in fetal liver ILC3 precursors 50, 128 . Consistent with Notch signalling in ILC3-restricted precursors, the transcription factor TCF1 is also important for generating mature ILC3 subsets 118 . Notch signalling is also required for the development of NKp46 + ILC3s 128, 129 . The transcription factor TOX is also required for the generation of some ILC3 subsets (for instance, LTi cells), whereas NKp46 + ILC3s are TOX independent 102 . It is not known how TOX controls the development of LTi cells, but ID2 does not seem to be involved 116, [118] [119] [120] . AHR is a transcription factor that is involved in the metabolism of xenobiotic compounds and is activated by a diverse set of endogenous ligands. Many ILC3 subsets are affected by AHR deficiency, including LTi cells and NKp46 + ILC3 subsets 120, [123] [124] [125] . By contrast, lymphoid structures are largely intact, which indicates that fetal ILC3 differentiation may be AHR independent. It is not known whether ILC3 precursors require AHR expression, but as conditional deletion of Ahr in the ILC3 lineage (using Cre-Rorc) generates similar defects in ILC3s as those seen in AHR-deficient mice, the continued expression of AHR seems to be necessary for ILC3 homeostasis.
The where and when of ILC differentiation. ILC develop ment is active during the fetal period (to generate LTi cells involved in lymphoid tissue organogenesis 49, 130 ) and continues in adulthood. Sites for fetal ILC development include the fetal liver and fetal gut 47, 50 . In these different tissue sites, ILCPs have been identified, including an arginase 1 (ARG1) + subset that can give rise to several ILC lineages in vitro and is associated with developing lymphoid structures in the intestine 131 . RORγt + ILC3-restricted fetal liver precursors with the potential to generate LTi cells and NCR + ILC3s after migration to the intestine have been described 50 9, 35 ; however, it is not clear to what extent these are true precursors or simply mature ILCs in the 'resting' state.
Beyond the 'bone marrow-centric' view of adult ILC development, it remains possible that circulating CLPs or ILC-restricted precursors (the CILCP subsets described above) could enter tissues allowing for local ILC development. The notion of 'peripheral' NK cell development was previously proposed on the basis of identification of mouse NKPs outside the bone marrow 132 and the presence of human NKPs in secondary lymphoid tissues 133 . More recently, ILC3-restricted precursors were identified in human tonsils 122 . Although evidence for tissue seeding by CILCPs remains limited, peripheral ILC development may provide the means to promote the generation of ILC subsets within tissues. Environmental signals (for example, cytokines, cell-associated ligands, microbial products or dietary factors) probably differ depending on the type of tissue encountered (and perhaps the position of the cell within the tissue), thereby providing a range of potential signals that would influence ILC development and diversification in a manner that is most suitable for the given context.
A final issue related to ILC development concerns the signals that regulate the balance between different ILC subsets in the same tissue. ILC subset distribution differs depending on the tissue and its inflammatory context. Diverse ILC subsets are present in lymphoid and mucosal tissues under steady-state conditions 134 , and ILC populations expand after infection or inflammation at these sites. Whereas changes in ILC subset distribution are likely to result from altered recruitment and/or proliferation of mature ILCs, it is possible that biased ILC development from tissue-seeding ILC progenitors may also affect ILC subset representation under these conditions.
Stage 3: ILC homeostasis in tissues
Regulation of ILCs in peripheral tissues is crucial for optimizing immune defence against infections and also for providing adequate signals for tissue remodelling after insult or inflammation. ILC homeostasis describes the mechanisms that keep the number and diversity of ILCs in the various tissues at an optimal level and, for any given ILC population, involves a combination of processes that affect ILC generation, circulation, survival and/or maintenance, proliferation and cell death. A complete discussion of these different processes is outside of the scope of this Review, but we will touch on a few key aspects that have an impact on peripheral ILC survival and plasticity (FIG. 4) .
ILC maintenance in tissues: a key role for cytokines.
Cytokines of the common γ-chain (γc) family are essential for the development of all known ILC subsets. The analysis of IL-7-deficient and IL-15-deficient mice established a role for IL-7 in the development of ILC2 and ILC3 subsets and a role for IL-15 in the development of EOMES + and EOMES − ILC1s 8, 13, 15, 129, 131, 132, 135, 136 . Moreover, exogenous delivery of these cytokines can expand ILC subsets in vivo [137] [138] [139] . It remains unclear at what stage these cytokines exert their effects on ILC homeostasis. As ILCPs and mature ILCs express the relevant cytokine receptors, it is likely that IL-7 or IL-15 is required at both the earliest progenitor stages and also to maintain the respective cell lineages in the tissues. Recent data derived from studies of the conditional deletion of the gene encoding γc (Il2rg) in NKp46 + cells showed the essential role of γc cytokines in the homeostasis of EOMES + ILC1s, EOMES − ILC1s and NKp46 + ILC3s 140 . Additional studies, including ILC transfer experiments and/or cell-type specific targeting of CD122 or CD127 at later stages of ILC differentiation, should further define the crucial roles of these cytokines in ILC homeostasis. The biologically relevant source of IL-7 or IL-15 for ILC survival remains unclear. IL-15 is required for survival and proliferation of mature NK cells 141 , and several cell types contribute through their production of IL-15, including myeloid cells and epithelial cells 142 . Recent data demonstrated that adipocytes also produce IL-15, which helps to maintain not only NK cells but also tissueresident ILC1s 143 . Studies in reporter mice suggest that diverse stromal cells, epithelial cells and endothelial cells are the primary sources of IL-7 (REF. 144 ). As such, ILC homeostasis is not likely to be under the control of a single cellular source, but rather regulated via diverse niches throughout the body. This might explain why systemic IL-7 or IL-15 levels are often reported as 'not detected' as they would not measure the cytokine concentration that locally fine-tunes tissue ILC homeostasis.
IL-2 produced by T cells during their activation may also serve to maintain ILC subsets in lymphoid and nonlymphoid tissues. Regulatory T cells bear high-affinity IL-2 receptors that bind IL-2 in tissues; depletion of these cells can alter ILC homeostasis as shown by the increase in ILC1 numbers that occurs in forkhead box P3 (FOXP3)-deficient mice 145 . Similarly, IL-2 produced by T cells has been implicated in ILC2 population expansion during pulmonary inflammation 27 . The role of T cell-derived IL-2 as a generic modifier of ILC homeostasis and the ability of regulatory T cells to indirectly inhibit this process provide an additional mechanism for control of ILC homeostasis. 
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(that is, LTi and NKp46 + ) subsets to be in the order of 2-3 weeks 47, 141 . We have little information on lifespan for other ILC subsets, and additional work is needed to answer this question. In addition, ILC lifespan may be conditioned by cellular activation, infection or inflammation that may also modify effector outputs of ILCs. Along these lines, long-lived LY49H + NK cells that expand in a ligandspecific fashion can be recovered after mouse cytomegalovirus infection; such 'memory' NK cells have enhanced functional properties 146 . Immune responses that activate ILC2 and ILC3 populations are also associated with increases in ILC numbers; it will be interesting to study whether these expanded ILCs have 'memory' properties.
Control of peripheral ILC plasticity by transcription factors. 'Plasticity' describes how differentiated cells can acquire new characteristics (for example, phenotypes and functions) depending on the environment. This phenomenon has been observed for various cell types in different tissues and has important implications for regenerative medicine. Such plasticity could provide multiple options for immune defence depending on the invading pathogen. ILC functional plasticity has been demonstrated in both human and mouse systems, especially for an ILC3-to-ILC1 transition that resembles the well-characterized T H 17-to-T H 1 transition (reviewed in REF. 147 ). Transcription factors such as RORγt and T-bet play a central part in this process. Loss of RORγt and acquisition of T-bet expression is associated with the ILC3-to-ILC1 transition that generates 'ex-ILC3' cells that stop IL-22 production and gain the ability to secrete IFNγ 55, 56 . Changes in environmental signals may initiate this process. RORγt expression in ILC3s is stabilized by microbiota and IL-7 signals, whereas upregulation of IL-15 expression could downregulate RORγt and enhance T-bet-mediated IFNγ expression 56 . This ILC3-to-ILC1 transition seems to be crucial for immune defence against infection with Salmonella enterica subsp. enterica serovar Typhimurium 55 . The ILC3-to-ILC1 transition in humans is driven by soluble factors, including IL-2 and IL-12 (REFS 62, 148) .
Functional plasticity in other ILC subsets is not well documented, although the transcription factor GFI1 may be involved in regulating ILC2 cytokine production profiles. In the absence of GFI1, ILC2s begin to upregulate RORγt and produce IL-17 (REF. 114 ). Whether this occurs in vivo during type 2 immune responses is not known. Phenotypic plasticity of EOMES + ILC1s has also been observed 9 , although the functional consequences are not known. The fact that ILC plasticity has been predominantly observed in the small intestine suggests that the environment might exert substantial influence on cell-fate decisions, which could be interpreted as tissue imprinting. A role for epigenetic modifications in this process is likely but has not yet been established. In future, it will be interesting to explore whether ILC plasticity has a role in disease progression during infection or inflammation.
Concluding remarks
The discovery of diverse ILC subsets represents a major advance in our understanding of how immune responses are established in order to cope with infection, inflammation and tissue repair. Interestingly, ILCs occupy niches in close vicinity to commensal microorganisms in the gastrointestinal, respiratory and urogenital tracts and in the skin, where ILCs are responsive to signals emanating from barrier cells (epithelial cells) or from sentinels (myeloid cells). Under steady-state conditions, these signals might help to maintain tissue ILCs. By contrast, during infection or inflammation, different signals are likely to activate ILCs in order to overcome microbial threats but with potentially negative effects on microbial communities (dysbiosis). The overall ILC response may be beneficial to the host in helping to eradicate pathogens, but it could also be detrimental; for example, the inability to return to homeostasis could contribute to chronic inflammation and diseases such as IBD, obesity or type 2 diabetes. Deciphering the signals that promote ILC subset development and regulate their peripheral function will be key to understanding the balance between these outcomes.
